# Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

> **NCT04496960** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Institute of Dental and Craniofacial Research (NIDCR)** · enrollment: 23 (actual)

## Conditions studied

- Sjogren's Syndrome

## Interventions

- **DRUG:** tofacitinib
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04496960
- **Lead sponsor:** National Institute of Dental and Craniofacial Research (NIDCR)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-18
- **Primary completion:** 2025-01-14
- **Final completion:** 2026-09-22
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04496960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04496960, "Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04496960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*